RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs


RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs

NOKOMIS, Fla.--(BUSINESS WIRE)-- The magnetic levitation technology that Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Nano3D BioSciences (n3D) recently used to grow lifelike human lung tissue could one day lead to an even more astonishing breakthrough—lab-grown, implantable human organs.

A recent article by TechNewsDaily described the cell culturing techniques employed by n3D co-founder Dr. Glauco Souza to levitate and grow layered human tissues including lung tissue, heart valves and stem cells which show tremendous promise to advance regenerative medicine.

These breakthroughs are all big steps toward a far-off goal: organ implantation.

"Nano3D's Bio-Assembler technology was recently used to create the first lab-grown lung tissue with organized layers of cells, and incredibly enough, that's only the tip of the iceberg," said RBCC CEO Patrick Brown. "Dr. Souza and n3D are truly on the cutting edge of regenerative medicine, and we couldn't be more excited to help market it to elite laboratories and researchers around the globe."

Rainbow BioSciences, RBCC's biotech division, signed a joint venture agreement with n3D last year to help develop and market the Bio-Assembler. The device utilizes a proprietary process to enable scientists to grow cells in a three-dimensional environment using nanoparticles that produce magnetic fields to lift cells from the bottom of petri dishes.

Compared with conventional cell cultures grown on flat surfaces, these three dimensional cultures form tissues that more closely resemble those found in the human body. The technique has the potential to drastically reduce the cost of developing new drugs as well as eliminate the use of animals when testing the safety of manufactured chemicals—not to mention potentially grow functional organs from scratch.

For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Amgen, Inc. (NAS: AMGN) .

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO

KEYWORDS: United States North America Florida


The article RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.